FDA Webview

Free FDA Notices

Patient-Focused Meeting on Alpha-1 Antitrypsin Deficiency


Federal Register Notice: FDA will hold a public meeting 9/29 on Patient-Focused Drug Development for Alpha-1 Antitrypsin Deficiency (AATD) to provide FDA with patients’ perspectives on the impact on daily life of AATD as well as perspectives on the available therapies for this disorder. Individuals with AATD have low serum levels of Alpha-1-Antitrypsin and increased risks of developing a form of chronic obstructive lung disease called emphysema and, less frequently, liver disease. Some AATD patients with emphysema have symptoms of asthma. The meeting will be held from 9 a.m. to 3:30 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. Contact Barbara Kass, (240) 402-6887. To view this notice, click here.